drugset / Trial / NCT02194179
Bioavailability of 2 Different Nevirapine Extended Release Formulations Compared to Viramune® in HIV-1 Infected Subjects
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The objective was to establish the pharmacokinetic (PK) profile at steady state of two different nevirapine (NVP) extended release (XR) formulations at 300 mg or 400 mg daily (QD) under fasted and fed conditions in comparison with the commercially available NVP immediate release (IR) tablet at 200 mg BID (400 mg/day).
Timeline
- Start
- 2006-12
- Primary completion
- 2007-05
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nevirapine | Small molecule | 200 mg | — |
| Subject | Nevirapine | Small molecule | 300 mg | — |
| Subject | Nevirapine | Small molecule | 400 mg | — |